#3 Clinical Trend: PCSK9 Inhibitors
Last month, the FDA approved use of an investigational proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor for lowering low-density lipoprotein (LDL) cholesterol levels. The vote was 11-4 in favor of approval. The committee felt the benefits were most notable in patients with heterozygous familial hypercholesterolemia (FH).
For more in-depth clinical information, see Familial Hypercholesterolemia.
Medscape © 2015
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ryan Syrek. Top 10 Clinical Trends for July 2015 - Medscape - Jul 22, 2015.